Physician profile
Aditya Sharma
NPI 1659410322
$19,904.37
in general payments reported to CMS, 2019-2025
41 companies · $2,457 in 2025
The $2,457 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,410 · 2020: $3,433 · 2021: $3,332 · 2022: $2,459 · 2023: $2,677 · 2024: $3,136 · 2025: $2,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,158 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,158.04 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,648.51 | 2019-2024 | Neurostar Tms Therapy System |
| Sunovion Pharmaceuticals INC. | $1,643.95 | 2019-2022 | |
| Abbvie INC. | $1,595.28 | 2021-2025 | Vraylar |
| Lundbeck LLC | $1,159.45 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,131.58 | 2021-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $1,051.62 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $1,038.33 | 2019-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $949.76 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $931.99 | 2019-2025 | Rexulti, Nuedexta |
| Corium, LLC | $878.43 | 2021-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $794.81 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neos Therapeutics, LP | $706.10 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Validus Pharmaceuticals LLC | $704.02 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $587.16 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $537.02 | 2019-2025 | Trintellix |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $430.39 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $412.09 | 2021-2025 | Qelbree, Qelbree |
| Avanir Pharmaceuticals, INC. | $332.10 | 2019-2022 | |
| Bausch Health US, LLC | $302.16 | 2019-2025 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $277.02 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $271.64 | 2019-2025 | Fanapt |
| Axsome Therapeutics, INC. | $251.34 | 2022-2025 | Auvelity |
| Shockwave Medical, INC | $246.84 | 2025 | |
| Almatica Pharma LLC | $244.35 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Noven Therapeutics, LLC | $217.70 | 2022-2025 | Xelstrym, Secuado |
| Adlon Therapeutics L.P. | $174.83 | 2019-2021 | |
| Shire North American Group INC | $171.37 | 2019 | |
| Idorsia Pharmaceuticals US INC | $168.94 | 2023-2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $162.70 | 2024-2025 | Relexxii |
| Arbor Pharmaceuticals, INC. | $157.14 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $133.15 | 2019-2021 | |
| Rhodes Pharmaceuticals L.P. | $105.67 | 2019 | |
| Livanova USA, INC. | $98.08 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Eisai INC. | $94.52 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $89.49 | 2019-2021 | |
| Penumbra, INC. | $63.60 | 2024 | Penumbra System |
| Indivior INC. | $35.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.72 | 2024-2025 | Cobenfy |
| Alfasigma USA, INC. | $31.74 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.64 | 2025 | |
| Collegium Pharmaceutical, INC. | $19.36 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.